$PALI
PALISADE BIO, INC. Stock $pali

$pali Overview Financials Valuation SEC Filings Company Website

2016 Q1 Form 10-Q Financial Statement

#000114420416099716 Filed on May 09, 2016

Income Statement

Concept	2016 Q1	2015 Q1
Revenue	$2.500K	$2.917K
YoY Change	-14.3%	-30.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.170M	$1.430M
YoY Change	121.68%	-59.38%
% of Gross Profit
Research & Development	$3.066M	$3.183M
YoY Change	-3.68%	95.22%
% of Gross Profit
Depreciation & Amortization	$90.00K	$80.00K
YoY Change	12.5%	-11.11%
% of Gross Profit
Operating Expenses	$6.236M	$4.616M
YoY Change	35.1%	-10.91%
Operating Profit	-$6.234M	-$4.613M
YoY Change	35.13%	-10.89%
Interest Expense	$386.5K	$453.7K
YoY Change	-14.82%	4.85%
% of Operating Profit
Other Income/Expense, Net	-$372.2K	-$440.2K
YoY Change	-15.45%	-40.69%
Pretax Income	-$6.610M	-$5.050M
YoY Change	30.89%	-14.7%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$6.606M	-$5.053M
YoY Change	30.73%	-14.63%
Net Earnings / Revenue	-264231.32%	-173230.89%
Basic Earnings Per Share
Diluted Earnings Per Share	-$110.2M	-$84.17M
COMMON SHARES
Basic Shares Outstanding	92.04M shares	89.70M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q1	2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.620M	$28.63M
YoY Change	-73.38%	-14.13%
Cash & Equivalents	$7.621M	$13.59M
Short-Term Investments	$0.00	$15.03M
Other Short-Term Assets	$1.080M	$520.0K
YoY Change	107.69%	-31.58%
Inventory
Prepaid Expenses	$1.078M	$388.1K
Receivables	$39.17K	$8.173K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$8.738M	$29.15M
YoY Change	-70.03%	-14.53%
LONG-TERM ASSETS
Property, Plant & Equipment	$337.0K	$282.1K
YoY Change	19.47%	-9.12%
Goodwill
YoY Change
Intangibles	$1.067M	$1.242M
YoY Change	-14.13%	4.32%
Long-Term Investments
YoY Change
Other Assets	$57.69K	$59.10K
YoY Change	-2.38%	-8.87%
Total Long-Term Assets	$1.461M	$1.646M
YoY Change	-11.23%	-9.28%
TOTAL ASSETS
Total Short-Term Assets	$8.738M	$29.15M
Total Long-Term Assets	$1.461M	$1.646M
Total Assets	$10.20M	$30.80M
YoY Change	-66.89%	-14.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.630M	$2.130M
YoY Change	23.47%	20.34%
Accrued Expenses	$290.0K	$230.0K
YoY Change	26.09%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$4.466M	$1.929M
YoY Change	131.52%	-32.31%
Total Short-Term Liabilities	$7.621M	$4.336M
YoY Change	75.75%	-7.23%
LONG-TERM LIABILITIES
Long-Term Debt	$2.546M	$6.955M
YoY Change	-63.39%	65.89%
Other Long-Term Liabilities	$200.0K	$150.0K
YoY Change	33.33%	-6.25%
Total Long-Term Liabilities	$2.546M	$6.955M
YoY Change	-63.39%	65.89%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.621M	$4.336M
Total Long-Term Liabilities	$2.546M	$6.955M
Total Liabilities	$10.37M	$11.44M
YoY Change	-9.35%	26.7%
SHAREHOLDERS EQUITY
Retained Earnings	-$178.6M	-$156.1M
YoY Change	14.39%	16.2%
Common Stock	$920.4K	$903.4K
YoY Change	1.89%	4.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$169.4K	$19.36M
YoY Change
Total Liabilities & Shareholders Equity	$10.20M	$30.80M
YoY Change	-66.89%	-14.27%

Cashflow Statement

Concept	2016 Q1	2015 Q1
OPERATING ACTIVITIES
Net Income	-$6.606M	-$5.053M
YoY Change	30.73%	-14.63%
Depreciation, Depletion And Amortization	$90.00K	$80.00K
YoY Change	12.5%	-11.11%
Cash From Operating Activities	-$3.490M	-$4.720M
YoY Change	-26.06%	74.17%
INVESTING ACTIVITIES
Capital Expenditures	$14.60K	$16.05K
YoY Change	-9.06%	-85.55%
Acquisitions
YoY Change
Other Investing Activities	$7.520M	-$20.00K
YoY Change	-37700.0%	-99.87%
Cash From Investing Activities	$7.490M	-$100.0K
YoY Change	-7590.0%	-99.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00
YoY Change
Debt Paid & Issued, Net	$1.097M	$0.00
YoY Change		-100.0%
Cash From Financing Activities	-1.100M	5.890M
YoY Change	-118.68%	-69.69%
NET CHANGE
Cash From Operating Activities	-3.490M	-4.720M
Cash From Investing Activities	7.490M	-100.0K
Cash From Financing Activities	-1.100M	5.890M
Net Change In Cash	2.900M	1.070M
YoY Change	171.03%	-28.67%
FREE CASH FLOW
Cash From Operating Activities	-$3.490M	-$4.720M
Capital Expenditures	$14.60K	$16.05K
Free Cash Flow	-$3.505M	-$4.736M
YoY Change	-26.0%	67.88%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	125684	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3065590	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3182823	USD
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3170522	USD
CY2016Q1	us-gaap	Revenues Revenues	2500	USD
CY2015Q1	us-gaap	Revenues Revenues	2917	USD
CY2015Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1433074	USD
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	92009782	shares
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	89654634	shares
CY2016Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-1773	USD
CY2016Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	241008	USD
CY2015Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	173542	USD
CY2016Q1	us-gaap	Liabilities Current LiabilitiesCurrent	7621272	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6425472	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	6236112	USD
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	4615897	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6233612	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4612980	USD
CY2016Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	11136	USD
CY2015Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	13569	USD
CY2016Q1	us-gaap	Interest Expense InterestExpense	386506	USD
CY2015Q1	us-gaap	Interest Expense InterestExpense	453734	USD
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-372171	USD
CY2015Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-440165	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-6605783	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-5053145	USD
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2015Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	13	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	-6607556	USD
CY2015Q1	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	-5053132	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3199	USD
CY2015Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7620746	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4716533	USD
CY2016Q1	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2015Q4	us-gaap	Short Term Investments ShortTermInvestments	7517453	USD
CY2016Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	39167	USD
CY2016Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1077762	USD
CY2015Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1159782	USD
CY2016Q1	us-gaap	Assets Current AssetsCurrent	8737675	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	13431084	USD
CY2016Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	336974	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	343200	USD
CY2016Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1066577	USD
CY2015Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1103467	USD
CY2016Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	57692	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	71797	USD
CY2016Q1	us-gaap	Assets Assets	10198918	USD
CY2015Q4	us-gaap	Assets Assets	14949548	USD
CY2016Q1	cur	Accounts Payable And Accrued Expenses Excluding Accrued Bonuses AccountsPayableAndAccruedExpensesExcludingAccruedBonuses	2627137	USD
CY2015Q4	cur	Accounts Payable And Accrued Expenses Excluding Accrued Bonuses AccountsPayableAndAccruedExpensesExcludingAccruedBonuses	1455826	USD
CY2016Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	4466081	USD
CY2015Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	4634742	USD
CY2016Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2546296	USD
CY2015Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3391808	USD
CY2016Q1	us-gaap	Liabilities Other Than Longterm Debt Noncurrent LiabilitiesOtherThanLongtermDebtNoncurrent	200739	USD
CY2015Q4	us-gaap	Liabilities Other Than Longterm Debt Noncurrent LiabilitiesOtherThanLongtermDebtNoncurrent	164990	USD
CY2016Q1	us-gaap	Liabilities Liabilities	10368307	USD
CY2015Q4	us-gaap	Liabilities Liabilities	9982270	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	176002832	USD
CY2016Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1298	USD
CY2016Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q1	us-gaap	Common Stock Value CommonStockValue	920440	USD
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	920057	USD
CY2016Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	177473335	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3071	USD
CY2016Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-178564462	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-171958682	USD
CY2016Q1	us-gaap	Stockholders Equity StockholdersEquity	-169389	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	4967278	USD
CY2016Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10198918	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14949548	USD
CY2016Q1	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	287046	USD
CY2015Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	161362	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1470886	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	689857	USD
CY2016Q1	cur	Amortization Of Deferred Financing Fees And Debt Discount AmortizationOfDeferredFinancingFeesAndDebtDiscount	189462	USD
CY2015Q1	cur	Amortization Of Deferred Financing Fees And Debt Discount AmortizationOfDeferredFinancingFeesAndDebtDiscount	215182	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1851	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-217351	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-82020	USD
CY2015Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	71207	USD
CY2016Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-14029	USD
CY2015Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	357	USD
CY2016Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	1170334	USD
CY2015Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-375988	USD
CY2016Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	49177	USD
CY2015Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-3648	USD
CY2016Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-67646	USD
CY2015Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3488221	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4719821	USD
CY2016Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
CY2015Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	15032419	USD
CY2016Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	7517453	USD
CY2015Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	15007478	USD
CY2016Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	12747	USD
CY2015Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	57283	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14598	USD
CY2015Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16052	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	7490108	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-98276	USD
CY2016Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
CY2015Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	3073537	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	2931925	USD
CY2016Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1096951	USD
CY2015Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2016Q1	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	0	USD
CY2015Q1	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	70241	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-1096951	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	5892463	USD
CY2016Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-723	USD
CY2015Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	115	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2904213	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1074481	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12518980	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13593461	USD
CY2016Q1	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	0	USD
CY2015Q1	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	42758	USD
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	7000000	shares
CY2016Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2014	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1000000	USD
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1470886	USD
CY2015Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	689857	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	17102947	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	3712898	shares
CY2016Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	102010	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	20713835	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	14998577	shares
CY2015Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-421639	USD
CY2016Q1	us-gaap	Interest Paid InterestPaid	205827	USD
CY2015Q1	us-gaap	Interest Paid InterestPaid	238552	USD
CY2016Q1	cur	Issuance Of Common Stock For Cashless Excercise Of Warrants And Options IssuanceOfCommonStockForCashlessExcerciseOfWarrantsAndOptions	38337	USD
CY2015Q1	cur	Issuance Of Common Stock For Cashless Excercise Of Warrants And Options IssuanceOfCommonStockForCashlessExcerciseOfWarrantsAndOptions	201720	USD
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	40500000	shares
CY2015Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	39100000	shares
CY2013Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	8000000	USD
CY2013Q1	us-gaap	Debt Instrument Unused Borrowing Capacity Amount DebtInstrumentUnusedBorrowingCapacityAmount	2000000	USD
CY2016Q1	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.11	pure
CY2016Q1	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	7551000	USD
CY2016Q1	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	300000	USD
CY2014	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	805972	shares
CY2014Q4	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	4300000	USD
CY2014Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	446000	USD
CY2014Q4	us-gaap	Long Term Debt Percentage Bearing Variable Interest Rate LongTermDebtPercentageBearingVariableInterestRate	0.1	pure
CY2014Q4	cur	Debt Instrument Principal Amount DebtInstrumentPrincipalAmount	10000000	USD
CY2014Q4	cur	Debt Instrument Additional Principal Borrowed DebtInstrumentAdditionalPrincipalBorrowed	4400000	USD
CY2014Q4	cur	Debt Instrument Refinanced Loan DebtInstrumentRefinancedLoan	5600000	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	20428072	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.08
CY2016Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.77
CY2016Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2016Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.63
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.85
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.16
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.86
CY2016Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y8M12D
CY2016Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y6M
CY2016Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y8M12D
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	550000	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	165000	USD
CY2016Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	156750	USD
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2016Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	7000000	shares
CY2016Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	92005705	shares
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2016Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	92044042	shares
CY2016Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	92044042	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	92005705	shares
CY2016Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	7600000	USD
CY2016Q1	cur	Policy For Maximum Maturity Days Of Investments Considered As Cash Equivalents PolicyForMaximumMaturityDaysOfInvestmentsConsideredAsCashEquivalents	90 days and not more than one year.
CY2016Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <u><font style="BACKGROUND: transparent; FONT-SIZE: 10pt">Use of Estimates</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent; size: 8.5in 11.0in" align="justify"><font style="BACKGROUND-IMAGE: none; BACKGROUND-ATTACHMENT: scroll; BACKGROUND-REPEAT: repeat; BACKGROUND-POSITION: 0% 0%; FONT-SIZE: 10pt"> The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The condensed financial statements include significant estimates for the expected economic life and value of our licensed technology, our net operating loss and related valuation allowance for tax purposes and our stock-based compensation related to employees and directors, consultants and investment banks, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q1	cur	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms	P5Y8M12D
CY2016Q1	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	20713835	shares
CY2015Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2016Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	45400000	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.77
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.38
CY2016Q1	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	4620000	USD
CY2016Q1	cur	Compensation Expenses Unvested Restricted Stock Term Period CompensationExpensesUnvestedRestrictedStockTermPeriod	P2Y
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y
CY2016Q1	us-gaap	Debt Instrument Convertible Terms Of Conversion Feature DebtInstrumentConvertibleTermsOfConversionFeature	The loan agreement provided for a conversion feature whereby the lender or the Company could each convert up to a maximum of $1 million in principal payments into common stock of the Company.
CY2016Q1	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2016-06-01
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0	shares

Files In Submission

Name	View Source	Status
0001144204-16-099716-index-headers.html	Edgar Link	pending
0001144204-16-099716-index.html	Edgar Link	pending
0001144204-16-099716.txt	Edgar Link	pending
0001144204-16-099716-xbrl.zip	Edgar Link	pending
cur-20160331.xml	Edgar Link	completed
cur-20160331.xsd	Edgar Link	pending
cur-20160331_cal.xml	Edgar Link	unprocessable
cur-20160331_def.xml	Edgar Link	unprocessable
cur-20160331_lab.xml	Edgar Link	unprocessable
cur-20160331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tchart.jpg	Edgar Link	pending
v438106_10q.htm	Edgar Link	pending
v438106_ex31-1.htm	Edgar Link	pending
v438106_ex31-2.htm	Edgar Link	pending
v438106_ex32-1.htm	Edgar Link	pending
v438106_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PALI
PALISADE BIO, INC. Stock $pali

2016 Q1 Form 10-Q Financial Statement

#000114420416099716 Filed on May 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PALI PALISADE BIO, INC. Stock $pali

2016 Q1 Form 10-Q Financial Statement

#000114420416099716 Filed on May 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PALI
PALISADE BIO, INC. Stock $pali